Data / Drug companies / Endothelin Receptor Antagonist
Endothelin Receptor Antagonist drugs: 7 drugs from 28 companies in the FDA NDC directory
Endothelin Receptor Antagonist is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 61 products in this class from 28 companies, covering 7 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on October 1, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 28Companies
- 61Products
- 7Drugs by generic name
Drugs in the Endothelin Receptor Antagonist class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Macitentan | 15 | 15 |
| Ambrisentan | 26 | 13 |
| Bosentan | 14 | 7 |
| Macitentan and tadalafil | 2 | 1 |
| Sparsentan | 2 | 1 |
| Aprocitentan | 1 | 1 |
| Atrasentan | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 6 | tablet, film coated; tablet, for suspension | New drug applications (NDA) | March 22, 2024 |
| Sun Pharmaceutical Industries, Inc. | 5 | tablet, film coated | Generic drugs (ANDA) | June 6, 2026 |
| Zydus Lifesciences Limited | 5 | tablet; tablet, film coated | Generic drugs (ANDA) | February 17, 2026 |
| Actavis Pharma, Inc. | 4 | tablet, film coated | Generic drugs (ANDA) | June 19, 2019 |
| Zydus Pharmaceuticals USA Inc. | 4 | tablet, film coated; tablet, for suspension | Generic drugs (ANDA) | February 17, 2026 |
| Apotex Corp. | 3 | tablet, film coated | Generic drugs (ANDA) | June 11, 2026 |
| Aurobindo Pharma Limited | 3 | tablet, film coated | Generic drugs (ANDA) | June 8, 2026 |
| Mylan Pharmaceuticals Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | June 8, 2026 |
| A-S Medication Solutions | 2 | tablet, film coated | Generic drugs (ANDA) | July 21, 2022 |
| Cipla USA Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | April 26, 2019 |
| Gilead Sciences, Inc. | 2 | tablet, film coated | New drug applications (NDA) | June 15, 2007 |
| Golden State Medical Supply, Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | May 19, 2022 |
| Quallent Pharmaceuticals Health LLC | 2 | tablet, film coated | Generic drugs (ANDA) | May 1, 2024 |
| Sigmapharm Laboratories, LLC | 2 | tablet, film coated | Generic drugs (ANDA) | April 10, 2019 |
| Travere Therapeutics, Inc. | 2 | tablet, film coated | New drug applications (NDA) | February 17, 2023 |
| Zydus Pharmaceuticals USA Inc. | 2 | tablet, coated | Generic drugs (ANDA) | May 1, 2019 |
| Alembic Pharmaceuticals Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | June 6, 2026 |
| Alembic Pharmaceuticals Limited | 1 | tablet, film coated | Generic drugs (ANDA) | June 6, 2026 |
| Amneal Pharmaceuticals NY LLC | 1 | tablet, film coated | Generic drugs (ANDA) | June 8, 2026 |
| Ani Pharmaceuticals, Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | October 1, 2026 |
| Idorsia Pharmaceuticals Ltd | 1 | tablet, film coated | New drug applications (NDA) | March 20, 2024 |
| Laurus Labs Limited | 1 | tablet, film coated | Generic drugs (ANDA) | May 15, 2026 |
| Lupin Pharmaceuticals, Inc. | 1 | tablet, for suspension | Generic drugs (ANDA) | August 18, 2025 |
| Novartis Pharmaceuticals Corporation | 1 | tablet, film coated | New drug applications (NDA) | April 2, 2025 |
| Novugen Pharma (USA) LLC | 1 | tablet, film coated | Generic drugs (ANDA) | May 7, 2026 |
| Sandoz Inc | 1 | tablet, film coated | Generic drugs (ANDA) | August 20, 2025 |
| Teva Pharmaceuticals, Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | June 8, 2026 |
| Torrent Pharmaceuticals Limited | 1 | tablet | Generic drugs (ANDA) | June 1, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 52 | 85.2% |
| Tablet, for suspension | 4 | 6.6% |
| Tablet | 3 | 4.9% |
| Tablet, coated | 2 | 3.3% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.